Onconova Therapeutics Analyst Ratings
Onconova Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/12/2023 | 1258.19% | HC Wainwright & Co. | $11 → $11 | Reiterates | Buy → Buy |
| 08/11/2023 | 1258.19% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 06/14/2023 | 1258.19% | HC Wainwright & Co. | → $11 | Reiterates | → Buy |
| 06/06/2023 | 1258.19% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 05/25/2023 | 1258.19% | HC Wainwright & Co. | → $11 | Reiterates | → Buy |
| 05/16/2023 | 1258.19% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 04/21/2023 | 1258.19% | HC Wainwright & Co. | → $11 | Upgrades | Neutral → Buy |
| 03/01/2022 | 764.3% | Ladenburg Thalmann | → $7 | Initiates Coverage On | → Buy |
| 05/18/2021 | 393.89% | Guggenheim | → $4 | Initiates Coverage On | → Buy |
| 12/22/2020 | — | Noble Capital Markets | Upgrades | Market Perform → Outperform | |
| 08/24/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 07/25/2019 | 1381.66% | Noble Capital Markets | → $12 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月12日 | 1258.19% | HC Wainwright公司 | $11→$11 | 重申 | 購買→購買 |
| 2023年08月11日 | 1258.19% | HC Wainwright公司 | →$11 | 重申 | 購買→購買 |
| 2023/06/14 | 1258.19% | HC Wainwright公司 | →$11 | 重申 | →購買 |
| 06/06/2023 | 1258.19% | HC Wainwright公司 | →$11 | 重申 | 購買→購買 |
| 2023年05月25日 | 1258.19% | HC Wainwright公司 | →$11 | 重申 | →購買 |
| 2023年05月16日 | 1258.19% | HC Wainwright公司 | →$11 | 重申 | 購買→購買 |
| 04/21/2023 | 1258.19% | HC Wainwright公司 | →$11 | 升級 | 中性→購買 |
| 03/01/2022 | 764.3% | 拉登堡·塔爾曼 | →$7 | 開始承保 | →購買 |
| 2021/05/18 | 393.89% | 古根海姆 | →$4 | 開始承保 | →購買 |
| 12/22/2020 | - | 來寶資本市場 | 升級 | 市場表現優於→ | |
| 08/24/2020 | - | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 2019年07月25日 | 1381.66% | 來寶資本市場 | →$12 | 開始承保 | →跑贏大盤 |
What is the target price for Onconova Therapeutics (ONTX)?
Onconova治療公司(ONTX)的目標價格是多少？
The latest price target for Onconova Therapeutics (NASDAQ: ONTX) was reported by HC Wainwright & Co. on October 12, 2023. The analyst firm set a price target for $11.00 expecting ONTX to rise to within 12 months (a possible 1258.19% upside). 7 analyst firms have reported ratings in the last year.
昂科諾娃治療公司(納斯達克代碼：ONTX)的最新目標價是由HC Wainwright&Co.於2023年10月12日報道的。這家分析公司將目標價定為11美元，預計ONTX將在12個月內上漲至(可能上漲1258.19%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Onconova Therapeutics (ONTX)?
Onconova治療公司(ONTX)的最新分析師評級是多少？
The latest analyst rating for Onconova Therapeutics (NASDAQ: ONTX) was provided by HC Wainwright & Co., and Onconova Therapeutics reiterated their buy rating.
昂科諾娃治療公司(納斯達克代碼：ONTX)的最新分析師評級由HC Wainwright&Co.提供，Onconova治療公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Onconova Therapeutics (ONTX)?
Onconova治療公司(ONTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Onconova Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Onconova Therapeutics was filed on October 12, 2023 so you should expect the next rating to be made available sometime around October 12, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Onconova治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Onconova治療公司的上一次評級是在2023年10月12日提交的，所以你應該預計下一次評級將在2024年10月12日左右的某個時候提供。
Is the Analyst Rating Onconova Therapeutics (ONTX) correct?
分析師對Onconova Treeutics(ONTX)的評級正確嗎？
While ratings are subjective and will change, the latest Onconova Therapeutics (ONTX) rating was a reiterated with a price target of $11.00 to $11.00. The current price Onconova Therapeutics (ONTX) is trading at is $0.81, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Onconova治療公司(ONTX)評級被重申，目標價在11.00美元至11.00美元之間。Onconova治療公司(ONTX)目前的交易價格為0.81美元，超出了分析師的預測範圍。